Celsus Therapeutics Overview
- Year Founded
-
2004
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$20.3M
Celsus Therapeutics General Information
Description
Developer of non-steroidal, synthetic anti-inflammatory drugs. The company a biopharmaceutical drug enterprise developing synthetic anti-inflammatory drugs termed Multi-Functional Anti-Inflammatory Drugs (MFAID), that serve as an alternative to corticosteroids. The company is developing therapies to address respiratory inflammatory diseases (Allergic Rhinitis and Asthma), inflammatory skin diseases (dermatitis), inflammatory bowel disease (IBD), ophthalmic inflammatory conditions (conjunctivitis and dry eye), and Cystic Fibrosis.
Contact Information
Corporate Office
- The Gridiron Building
- One Pancras Square
- London N1C 4AG
- England, United Kingdom
Corporate Office
- The Gridiron Building
- One Pancras Square
- London N1C 4AG
- England, United Kingdom
Celsus Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Merger/Acquisition | 18-Sep-2015 | $20.3M | Completed | Generating Revenue | ||
| 8. Secondary Transaction - Open Market | 31-Mar-2014 | Completed | Generating Revenue | |||
| 7. 2PO | 30-Jan-2014 | Completed | Generating Revenue | |||
| 6. IPO | 12-Dec-2013 | Completed | Generating Revenue | |||
| 5. Secondary Transaction - Open Market | 06-Nov-2013 | Completed | Generating Revenue | |||
| 4. PIPE | 30-Sep-2013 | Completed | Generating Revenue | |||
| 3. Secondary Transaction - Open Market | 16-Apr-2013 | Completed | Generating Revenue | |||
| 2. Later Stage VC | 01-Feb-2013 | $2.43M | $5.63M | Completed | Generating Revenue | |
| 1. Early Stage VC | 10-May-2007 | $3.19M | $3.19M | Completed | Startup |
Celsus Therapeutics Former Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Alpha Capital Partners | PE/Buyout | Minority | ||
| Baker Brothers Investments | Hedge Fund | Minority | ||
| Capital Ventures International | Hedge Fund | Minority | ||
| Charles Street Securities Europe | Venture Capital | Minority | ||
| Franklin Templeton | Asset Manager | Minority |
Celsus Therapeutics Acquisitions (1)
Celsus Therapeutics’s most recent deal was a Reverse Merger with Akari Therapeutics. The deal was made on 18-Sep-2015.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Akari Therapeutics | 18-Sep-2015 | Reverse Merger | Drug Discovery |
Celsus Therapeutics FAQs
-
When was Celsus Therapeutics founded?
Celsus Therapeutics was founded in 2004.
-
Where is Celsus Therapeutics headquartered?
Celsus Therapeutics is headquartered in London, United Kingdom.
-
What industry is Celsus Therapeutics in?
Celsus Therapeutics’s primary industry is Drug Discovery.
-
Is Celsus Therapeutics a private or public company?
Celsus Therapeutics is a Private company.
-
What is the current valuation of Celsus Therapeutics?
The current valuation of Celsus Therapeutics is .
-
What is Celsus Therapeutics’s current revenue?
The current revenue for Celsus Therapeutics is .
-
How much funding has Celsus Therapeutics raised over time?
Celsus Therapeutics has raised $30.7M.
-
Who are Celsus Therapeutics’s investors?
Alpha Capital Partners, Baker Brothers Investments, Capital Ventures International, Charles Street Securities Europe, and Franklin Templeton are 5 of 7 investors who have invested in Celsus Therapeutics.
-
When was Celsus Therapeutics acquired?
Celsus Therapeutics was acquired on 18-Sep-2015.
-
Who acquired Celsus Therapeutics?
Celsus Therapeutics was acquired by Akari Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process